HER2 status in breast cancer -: an example of pharmacogenetic testing

被引：18
作者：
Kroese, Mark
Zimmern, Ron L.
Pinder, Sarah E.
机构：
[1] Strangeways Res Lab, Publ Hlth Genet Unit, Cambridge CB1 8RN, England
[2] Addenbrookes NHS Trust, Dept Histopathol, Cambridge, England
来源：
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE | 2007年 / 100卷 / 07期
关键词：
D O I：
10.1258/jrsm.100.7.326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The development of new drugs and associated pharmacogenetic tests will provide an increasing number of challenges to health care systems. In particular, how to evaluate their benefits, prioritize for commissioning purposes and implement a service to provide them in a timely manner. This paper presents an overview of HER2 testing for trastuzumab (Herceptin) treatment in breast cancer cases. Immunohistochemistry and fluorescence in situ hybridization laboratory techniques are described and their HER2 testing performances are compared. Future options for the national provision of HER2 testing by the National Health Service in the UK are also discussed.
引用
收藏
页码：326 / 329
页数：4
相关论文
共 21 条
[1]   The clinical evaluation of HER-2 status: which test to use? [J].
Bartlett, J ;
Mallon, E ;
Cooke, T .
JOURNAL OF PATHOLOGY, 2003, 199 (04) :411-417
[2]   Evaluating HER2 amplification and overexpression in breast cancer [J].
Bartlett, JMS ;
Going, JJ ;
Mallon, EA ;
Watters, AD ;
Reeves, JR ;
Stanton, P ;
Richmond, J ;
Donald, B ;
Ferrier, R ;
Cooke, TG .
JOURNAL OF PATHOLOGY, 2001, 195 (04) :422-428
[3]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[4]   The distinctive nature of HER2-positive breast cancers [J].
Burstein, HJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1652-1654
[5]   Adjuvant trastuzumab for breast cancer - We need to ensure that equity exists for access to effective and expensive treatments [J].
Dent, R ;
Clemons, M .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7524) :1035-1036
[6]   Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres [J].
Dowsett, M ;
Bartlett, J ;
Ellis, IO ;
Salter, J ;
Hills, M ;
Mallon, E ;
Watters, AD ;
Cooke, T ;
Paish, C ;
Wencyk, PM ;
Pinder, SE .
JOURNAL OF PATHOLOGY, 2003, 199 (04) :418-423
[7]   HER-2 testing and trastuzurnab therapy for metastatic breast cancer: A cost-effectiveness analysis [J].
Elkin, EB ;
Weinstein, KC ;
Winer, EP ;
Kuntz, KM ;
Schnitt, SJ ;
Weeks, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :854-863
[8]   HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques [J].
Ellis, CM ;
Dyson, MJ ;
Stephenson, TJ ;
Maltby, EL .
JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (07) :710-714
[9]   Updated recommendations for HER2 testing in the UK [J].
Ellis, IO ;
Bartlett, J ;
Dowsett, M ;
Humphreys, S ;
Jasani, B ;
Miller, K ;
Pinder, SE ;
Rhodes, A ;
Walker, R .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (03) :233-237
[10]   Trastuzumab in the treatment of breast cancer [J].
Hortobagyi, GN .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) :1734-1736
123